Significance of serum osteoprotegerin and receptor activator of nuclear factor κB ligand in Japanese prostate cancer patients with bone metastasis

Suzuki, Hiroyoshi; Endo, Takumi; Takano, Makoto; Yano, Masashi; Naoi, Makito; Kawamura, Koji; Igarashi, Takashi; Takanami, Mituru; Ichikawa, Tomohiko

doi:10.1007/s10147-011-0193-7

Cited by 16 publications

(14 citation statements)

References 30 publications

(43 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Recently, we examined the clinical outcome of the bone turnover marker in the PCa with bone metastases case. 12 In the present study, serum levels of ALP were higher in PCa with bone metastases than non-bone metastases cases. Furthermore, patients with higher levels of pretreatment ALP had a poorer prognosis than those with lower levels.…”

Section: Discussionsupporting

confidence: 48%

Additive effect of zoledronic acid on serum prostate‐specific antigen changes for hormone‐sensitive prostate cancer patients with bone metastasis treated by combined androgen blockade

et al. 2011

Self Cite

View full text Add to dashboard Cite

Abbreviations & Acronyms 1CTP = pyridinoline cross-linked carboxyterminal telopeptide of type 1 collagen ALP = alkaline phosphatase BAP = bobe-specific alkaline phosphatase CAB = combined androgen blockade CAB-Z = combination of combined androgen blockade and zoledronic acid EOD = extent of disease Mo = month PCa = prostate cancer PSA = prostate-specific antigen SRE = skeletal-related events ZOL = zoledronic acid Abstract: Combined androgen blockade is widely used to treat patients with advanced prostate cancer. Recently, zoledronic acid was proven to be effective in preventing skeletal-related events for prostate cancer patients with bone metastases. Aim of the present study was to assess the effect of adding zoledronic acid to combined androgen blockade in the treatment of hormone-naïve metastatic prostate cancer patients by analyzing the changes of biomarker levels. Patients were treated with either a combination of combined androgen blockade and zoledronic acid (n = 23) or combined androgen blockade alone (historical control combined androgen blockade group, n = 42). Zoledronic acid was injected intravenously at 4 mg every 4 weeks for 2 years. Prostate-specific antigen and bone turnover markers (alkaline phosphatase and pyridinoline cross-linked carboxyterminal telopeptide of type 1 collagen) were examined before treatment and at 3, 6, and 12 months after treatment. Sequential changes of prostate-specific antigen, alkaline phosphatase and pyridinoline cross-linked carboxyterminal telopeptide of type 1 collagen for the two groups versus pretreatment levels were compared. Prostate-specific antigen values in both groups significantly declined at 3, 6 and 12 months compared with pretreatment levels. However, the decline of the prostate-specific antigen was lower in the combined androgen blockade group. Alkaline phosphatase significantly declined at 6 and 12 months in the combination of combined androgen blockade and zoledronic acid group, with no significant changes seen in the combined androgen blockade group. The addition of zoledronic acid to combined androgen blockade showed prostate-specific antigen and bone turnover markers response compared with combined androgen blockade therapy only, suggesting a potential antitumor effect of zoledronic acid in the management of metastatic prostate cancer patients.

show abstract

Section: Discussionsupporting

confidence: 48%

Additive effect of zoledronic acid on serum prostate‐specific antigen changes for hormone‐sensitive prostate cancer patients with bone metastasis treated by combined androgen blockade

et al. 2011

Self Cite

View full text Add to dashboard Cite

show abstract

“…Among patients with prostatic cancer serum OPG levels were significantly elevated in patients with bone metastasis and predicted prostatic cancer related death (28). In our population based cohorts study, 178 subjects developed prostatic cancer during follow up.…”

Section: Discussionmentioning

confidence: 76%

Serum osteoprotegerin and future risk of cancer and cancer-related mortality in the general population: the Tromsø study

et al. 2014

View full text Add to dashboard Cite

The purpose was to investigate the association between serum osteoprotegerin (OPG) and risk of incident cancer and cancer mortality in a general population. OPG was measured in serum collected from 6279 subjects without prior cancer recruited from a general population.Incident cancer and cancer-related mortality were registered from inclusion in 1994-95 until end of follow-up December 31, 2008. Cox regression models were used to estimate crude and adjusted (for age, sex and other confounders) hazard ratios and 95% confidence intervals (HR; 95% CI). There were 948 incident cancers and 387 deaths in the cohort during 71902 person-years of follow up (median 13.5 years). Subjects with serum OPG in the upper tertile had 79% higher risk of incident gastrointestinal cancer than those in the lowest tertile (HR 1.79, 95% CI 1.19-2.67). In women < 60 years, serum OPG (per SD 0.81 ng/ml) was associated with reduced risk of incident cancer (all cancers merged) (0.73; 0.57-0.94) and breast cancer (0.51; 0.31-0.83) after adjustment. Subjects in the upper tertile of OPG had higher risk of cancer-related mortality (1.63; 1.16-2.28), particularly mortality from cancer in the gastrointestinal system (2.28; 1.21-4.28) compared to those in the lowest OPG tertile. No significant association was detected between OPG and risk of death from cancer in the respiratory system or death from prostatic cancer. Our findings from a large population based cohort study suggest that serum OPG was associated with increased risk of incident gastrointestinal cancer, inversely associated with breast cancer, and predicts cancer-related mortality.2

show abstract

“…Several workgroups also confirmed elevated OPG levels in the serum of metastasized patients [71,72,135,136]. The OPG concentrations correlate with the extent of osseous metastasis formation.…”

Section: Bone Markers In Diagnosticsmentioning

confidence: 74%

Bone turnover markers in serum and urine as diagnostic, prognostic and monitoring biomarkers of bone metastasis

Jung

Lein

2014

Biochimica et Biophysica Acta (BBA) - Reviews on Cancer

View full text Add to dashboard Cite

Significance of serum osteoprotegerin and receptor activator of nuclear factor κB ligand in Japanese prostate cancer patients with bone metastasis

Abstract: Serum OPG was a more reliable marker than serum RANKL in detecting bone metastatic spread and in predicting survival probability in PCa patients with bone metastasis.

Cited by 16 publications

References 30 publications

Additive effect of zoledronic acid on serum prostate‐specific antigen changes for hormone‐sensitive prostate cancer patients with bone metastasis treated by combined androgen blockade

Additive effect of zoledronic acid on serum prostate‐specific antigen changes for hormone‐sensitive prostate cancer patients with bone metastasis treated by combined androgen blockade

Serum osteoprotegerin and future risk of cancer and cancer-related mortality in the general population: the Tromsø study

Bone turnover markers in serum and urine as diagnostic, prognostic and monitoring biomarkers of bone metastasis

Contact Info

Product

Resources

About